安徽医药2025,Vol.29Issue(1) :196-199.DOI:10.3969/j.issn.1009-6469.2025.01.040

替雷利珠单抗药物利用评价标准的建立与应用

Establishment and application of evaluation criteria for drug use evaluation of tislelizumab

唐慕菲 张保国 沈芸竹 汤翠菊 陈晶 石文娟 潘希丁
安徽医药2025,Vol.29Issue(1) :196-199.DOI:10.3969/j.issn.1009-6469.2025.01.040

替雷利珠单抗药物利用评价标准的建立与应用

Establishment and application of evaluation criteria for drug use evaluation of tislelizumab

唐慕菲 1张保国 2沈芸竹 2汤翠菊 2陈晶 2石文娟 2潘希丁1
扫码查看

作者信息

  • 1. 南京医科大学附属南京医院(南京市第一医院),药学部,江苏 南京 210006
  • 2. 南京医科大学附属南京医院(南京市第一医院),肿瘤内科,江苏 南京 210006
  • 折叠

摘要

目的 针对替雷利珠单抗建立药物利用评价(drug use evaluation,DUE)标准,对南京医科大学附属南京医院替雷利珠单抗使用情况进行评价,为临床合理用药提供参考依据.方法 根据替雷利单抗药品说明书、临床相关指导原则、诊疗指南和专家共识等,建立替雷利珠单抗DUE标准,依据标准回顾性分析评价2023年1-9月南京医科大学附属南京医院使用替雷利珠单抗的住院病人用药情况.结果 替雷利珠单抗DUE标准包含14个指标.纳入96例病人,共使用替雷利珠单抗687次.体力评分、器官功能和实验室指标、给药剂量、给药途径、输注时间、给药频次和疗效评估合理率100%;禁忌证、溶媒种类和用量合理率98.96%;联合用药合理率97.92%;药物相互作用合理率96.88%;给药顺序和时间合理率84.38%;适应证合理率80.21%;不良反应监测与处理合理率39.58%.结论 建立并应用替雷利珠单抗DUE标准可发现用药过程中的不合理现象,为临床安全用药提供参考依据.

Abstract

Objective To establish a drug use evaluation(DUE)standard for the use of tislelizumab in Nanjing First Hospital,Nan-jing Medical University,and to evaluate the use of tislelizumab in order to provide a reference basis for rational clinical medication.Methods Based on the drug instructions,clinical guidelines for tumor diagnosis and treatment,and expert consensus,as well as the clinical application guidelines for new anti-tumor drugs,a DUE standard for tislelizumab was established.Based on the standard,a ret-rospective analysis was conducted to evaluate the medication use of tislelizumab in hospitalized patients from January 2023 to Septem-ber 2023.Results The DUE standard for tislelizumab included 14 indicators.A total of 96 patients were included and a total of 687 doses of tislelizumab were used.The reasonable rate of physical fitness score,organ function and laboratory indicators,dosage,route of administration,infusion time,frequency of administration,and efficacy evaluation was 100%;The reasonable rate of contraindications,types of solvents,and dosage was 98.96%;The reasonable rate of combination therapy was 97.92%;The reasonable rate of drug interac-tion was 96.88%;The reasonable rate of administration sequence and time was 84.38%;The reasonable rate of indications was 80.21%;The reasonable rate of adverse reaction monitoring and treatment was 39.58%.Conclusion Establishing and applying the DUE stan-dard for tislelizumab can detect unreasonable phenomena during the medication process and provide reference for safe clinical use.

关键词

药物利用评价/替雷利珠单抗/评价标准/合理用药/住院病人

Key words

Drug use evaluation/Tislelizumab/Evaluation criteria/Rational use of drugs/Hospitalized patient

引用本文复制引用

出版年

2025
安徽医药
安徽省药学会

安徽医药

CSTPCD
影响因子:1.941
ISSN:1009-6469
段落导航相关论文